the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
Official Title An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies
Principal Investigator Catenacci, Daniel
Brief Summary This is the first study to test Sym015 in humans. The primary purpose of this study is to see if Sym015 is safe and effective for patients with advanced solid tumors who do not have other available or accessible treatment options.
Gender All
Ages 18 Years
Enrollment 72
Accepts Healthy Volunteers No
Lead Sponsor Symphogen A/SIndustry
Collaborator
Study Design
Study Phase Phase 1/Phase 2
Study Type Interventional
Contact Name Daniel Catenacci, MD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Oncology
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI